Lilly, which has been active in the fight against diabetes for more than 100 years, has announced a new commitment with tirzepatide, an innovative therapy for type 2 diabetes.
ADVERTISING
Article Key Points
This new solution is the result of decades of metabolic research and is available at all pharmacies open to the public, upon prescription from a general practitioner and a specialist. Tirzepatide is the first drug in a new class, a double agonist of the Gip and GLP-1 receptors, capable of acting not only on the control of glycated hemoglobin, but also on weight, with an enhanced effect.
Investment in Italy
Lotto draws and winning numbers 10 and lotto today 7 March 2025
7 March 2025 - 20:28
The innovative therapy was recently made reimbursable by the Italian Medicines Agency (AIFA), representing a significant step forward in access to diabetes treatments.
Article published on March 19, 2025 - 11pm
I feel that this new therapy tirzepatide is very important for those with type 2 diabetes. However, I wonder if there will be side effects and how will the access to the therapy be for everyone, especially for older people who have difficulty finding a doctor.